The Biden administration is reportedly ready to recommend booster shots six months later instead of eight.
Tech-hacking companies may focus on the wrong issue to recruit diverse clinical trial candidates.
If you are new to this newsletter, sign up here. Send suggestions, grips, comments and predictions for the future of healthcare to mravindranath@insider.com or tweet. Round ind.. To the news …
Nurse Elizabeth Johnson administered the Covid 19 vaccine to Melissa Mendes in Reading, Pennsylvania.
Reading Entity / Media News Group / Eagle / Getty Images.
J&J says its single dose of COVID-19 vaccine booster shot raises antibody levels and can be given eight months after the first dose
Johnson & Johnson’s only dose The second dose of the COVID-19 vaccine boosted antibodies in a small study.
After the second dose, the antibody level was nine times higher than the original.
The company plans to meet with US health officials to discuss the possibility of administering the booster eight months after the first dose.
Read more >>
COVID-19 vaccine card at the Brixham Nursing and Rehabilitation Center in Burns Township, Pennsylvania on January 19, 2021.
Ben Entity / Media News Group / Reading Eagle / Getty Images.
Report: The Biden administration will likely recommend Covid 19 booster shots six months later instead of eight.
The Biden administration will approve COVID-19 booster shots for potentially immunized adults, according to the Wall Street Journal.
The administration had earlier said it would call for a booster for eight months.
The move is based on data from vaccine makers on a six-month booster shot schedule.
Get the news >>.
Clinical Trial Lab Research Drug Medicine.
Getty
There is a problem with diversity in clinical trials, but tech may not be the answer.
Startups are bringing together millions of people using state-of-the-art marketing and messaging technology to reach more ethnically and socio-economically diverse patients.
Clinical trials generally underestimate ethnic minorities, although the development of the COVID-19 vaccine has highlighted this problem for large pharmaceutical companies.
Equity experts say the technology may not address the real issues that keep minorities out of clinical trials, including a lack of access to healthcare.
Read the full story >>
More stories we are reading:
The full name of the Pfizer vaccine is a mesh-up of the full name – comorbidity – “covid 19”, “mRNA”, and much more (internal).
Mental health-focused tech companies merge headspace and ginger (state)
A new study at the JAMA Network Open finds abortion safe and effective with telehealth-facilitated drugs (MobyHealthNews)
Steven Blum explores how social media transforms “digital afterlife” and sadness (wired)
